Literature DB >> 3261206

Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides.

R Cauda1, M Tumbarello, L Ortona, P Kanda, R C Kennedy, T C Chanh.   

Abstract

The inhibitory effect on normal natural killer (NK) cell activity of two synthetic peptides corresponding to amino acid sequences 735-752 and 846-860, respectively, as deduced from the amino acid sequences of HTLV-IIIB gp160, was assessed. Sequences 735-752 and 846-860 correspond to regions located within the HIV transmembrane gp41, the carboxy terminus of HIV gp160. These two synthetic peptides have been shown previously to suppress the mitogen- and alloantigen-induced normal human lymphocyte blastogenic responses. Peptides 735-752 and 846-860 conjugated to protein carriers exerted a significant inhibition on the normal NK cell activity assayed against K562 tumor target cells in an in vitro 51Cr-release cytoltoxicity assay. At variance, control peptides similarly conjugated had no effect on NK activity. Addition of exogenous recombinant human interleukin-2 (IL-2) resulted in a partial restoration of the suppression of NK cell activity exerted by both peptides. Binding experiments indicated that peptides 735-752 and 846-860 did not affect the formation of effector cell-target cell conjugates, suggesting inhibitory effect(s) subsequent to the formation of the lytic complex as one potential mechanism of the observed NK suppression. These results suggest that peptides 735-752 and 846-860 homologous to sequences within the HIV transmembrane gp41 may play an important role in the pathogenesis of the defective NK cell activity observed in patients with acquired immunodeficiency syndrome (AIDS).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261206     DOI: 10.1016/0008-8749(88)90161-x

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  11 in total

Review 1.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

2.  Reversal of human immunodeficiency virus type 1 protein-induced inhibition of natural killer cell activity by alpha interferon and interleukin-2.

Authors:  M P Nair; S A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

3.  Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees.

Authors:  R Q Warren; H Wolf; K R Shuler; J W Eichberg; R A Zajac; R N Boswell; P Kanda; R C Kennedy
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

4.  In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates.

Authors:  J Chehimi; S Bandyopadhyay; K Prakash; B Perussia; N F Hassan; H Kawashima; D Campbell; J Kornbluth; S E Starr
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

5.  Herpes simplex virus-infected cells disarm killer lymphocytes.

Authors:  D L Confer; G M Vercellotti; D Kotasek; J L Goodman; A Ochoa; H S Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

6.  Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes infected individuals grouped according to CD4+ cell levels.

Authors:  R Q Warren; H Wolf; R A Zajac; R N Boswell; P Kanda; R C Kennedy
Journal:  J Clin Immunol       Date:  1991-01       Impact factor: 8.317

Review 7.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

8.  Envelope glycoprotein (gp120) from HIV-1 enhances Mycobacterium avium growth in human bronchoalveolar macrophages; an effect mediated by enhanced prostaglandin synthesis.

Authors:  M Denis
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

9.  Heterogeneous effects of exogenous IL-2 on HIV-specific cell-mediated immunity (CMI).

Authors:  S J Bell; D A Cooper; B E Kemp; R R Doherty; R Penny
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

10.  Interleukin-2-inducible natural immune (lymphokine-activated killer cell) responses as a functional correlate of progression to AIDS.

Authors:  B G Brenner; M Gornitsky; M A Wainberg
Journal:  Clin Diagn Lab Immunol       Date:  1994-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.